NOVAVAX INC Current Liabilities
NOVAVAX INC (NVAX) had Current Liabilities of $330.57 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $330.57M.
- 2026-03-31: Liabilities, Current $342.46M.
- 2025-12-31: Liabilities, Current $459.95M.
- 2025-09-30: Liabilities, Current $429.87M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $330.57M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $342.46M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $459.95M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $429.87M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $389.14M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $422.17M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.15B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.18B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.16B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $804.38M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $1.64B 10-K · filed 2025-02-27 | |
| 2023-09-30 | $1.47B 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $1.60B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $1.92B 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $2.46B 10-K · filed 2024-02-28 | |
| 2022-09-30 | $1.67B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $2.16B 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $2.26B 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $2.39B 10-K · filed 2023-02-28 | |
| 2021-09-30 | $1.75B 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $1.65B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $1.21B 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $579.67M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $239.22M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $213.33M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $18.98M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $25.80M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $21.57M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $41.49M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $31.50M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $45.54M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $46.72M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $43.02M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $44.90M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $73.67M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $68.28M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $66.79M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $56.50M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $66.41M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $75.68M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $81.88M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $71.05M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $76.49M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $24.87M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $27.05M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $28.78M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $34.12M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $18.64M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $17.48M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $13.71M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $18.12M 10-K · filed 2015-02-27 | $18.93M 10-K · filed 2014-03-12 |
| 2013-09-30 | $14.26M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $11.26M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $9.25M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $11.68M 10-K · filed 2014-03-12 | |
| 2012-09-30 | $10.44M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $9.42M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $7.84M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $7.58M 10-K · filed 2013-03-12 | |
| 2011-09-30 | $6.74M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $8.99M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $10.27M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |